High Sustained Virologic Response Rates in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection Receiving ABT-450/r/Ombitasvir plus Dasabuvir Plus Ribavirin

被引：0

作者：

Mantry, Parvez S. ^{[1
]}

Kwo, Paul Y. ^{[2
]}

Coakley, Eoin ^{[3
]}

Te, Helen S. ^{[4
]}

Vargas, Hugo E. ^{[5
]}

Brown, Robert S. ^{[6
]}

Gordon, Fredric D. ^{[7
]}

Levitsky, Josh ^{[8
]}

Terrault, Norah ^{[9
]}

Burton, James R. ^{[10
]}

Xie, Wangang ^{[3
]}

Setze, Carolyn ^{[3
]}

Badri, Prajakta ^{[3
]}

Vilchez, Regis A. ^{[3
]}

Forns, Xavier ^{[11
,12
]}

机构：

[1] Liver Inst Methodist Dallas, Dallas, TX USA

[2] Indiana Univ, Indianapolis, IN 46204 USA

[3] AbbVie Inc, N Chicago, IL USA

[4] Univ Chicago Med, Chicago, IL USA

[5] Mayo Clin, Mayo Clinic, AZ 5 USA

[6] Columbia Univ, Ctr Liver Dis & Transplantat, Med Ctr, New York, NY USA

[7] Lahey Hosp & Med Ctr, Burlington, MA USA

[8] Northwestern Univ, Comprehens Transplant Ctr, Chicago, IL 60611 USA

[9] Univ Calif San Francisco, San Francisco, CA 94143 USA

[10] Univ Colorado, Denver, CO 80202 USA

[11] IDIBAPS, Hosp Clin, Liver Unit, Barcelona, Spain

[12] CIBEREHD, Barcelona, Spain

来源：

HEPATOLOGY | 2014年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

198

引用

页码：298A / 299A

页数：2

共 50 条

[41] Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience
Yu, Ming-Lung
Chen, Yao-Li
Huang, Chung-Feng
Lin, Kuo-Hua
Yeh, Ming-Lun
Huang, Ching-I
Hsieh, Meng-Hsuan
Lin, Zu-Yau
Chen, Shinn-Cherng
Huang, Jee-Fu
Dai, Chia-Yen
Chuang, Wan-Long
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2018, 117 (06) : 518 - 526
[42] MALACHITE-I: PHASE 3B TRIAL OF OMBITASVIR/PARITAPREVIR/R AND DASABUVIR plus /- RIBAVIRIN OR TELAPREVIR plus PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE ADULTS WITH HCV GENOTYPE 1
Conway, B.
Janczewska, E.
Luo, Y.
Curescu, M.
Greenbloom, S.
Streinu-Cercel, A.
Caruntu, F. A.
Ghesquiere, W.
Knysz, B.
Mazur, W.
Fuster, F.
Motoc, A.
Soza, A.
Arama, V.
Dalgard, O.
Sullivan, D.
Liu, X.
Podsadecki, T.
JOURNAL OF HEPATOLOGY, 2015, 62 : S653 - S654
[43] MALACHITE-I: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir plus /- Ribavirin or Telaprevir plus Peginterferon/Ribavirin in Treatment-Naive Adults With HCV Genotype 1
Conway, Brian
Janczewska, Ewa
Luo, Yan
Curescu, Manuela
Greenbloom, Susan
Streinu-Cercel, Adrian
Caruntu, Florin A.
Ghesquiere, Wayne
Knysz, Brygida
Mazur, Wlodzimierz
Fuster, Francisco
Motoc, Adriana
Soza, Alejandro
Arama, Victoria
Dalgard, Olav
Sullivan, Danielle
Liu, Xuan
Podsadecki, Thomas
GASTROENTEROLOGY, 2015, 148 (04) : S1001 - S1002
[44] OMBITASVIR/PARITAPREVIR/RITONAVIR WITH RIBAVIRIN ACHIEVES HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) RATES IN EGYPTIAN ADULTS WITH CHRONIC HCV GENOTYPE 4 INFECTION (AGATE-II)
Waked, I.
Shiha, G.
Qaqish, R. B.
Esmat, G.
Yosry, A.
Doss, W.
Hassany, M.
Soliman, R.
Mohey, M. A.
Allam, N.
Zayed, N.
Setze, C. M.
Redman, R.
Mobashery, N.
JOURNAL OF HEPATOLOGY, 2016, 64 : S772 - S772
[45] Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir plus /- Ribavirin Regimen for Recurrent Genotype 1 HCV Infection After Liver Transplantation - Multicenter, Real-Life, AMBER-CEE Study
Tronina, O.
Durlik, M.
Wawrzynowicz-Syczewska, M.
Buivydiene, A.
Katzarov, K.
Kupcinskas, L.
Tolmane, I.
Karpinska, E.
Pisula, A.
Karwowska, K.
Bolewska, B.
Jablkowski, M.
Rostkowska, K.
Jakutiene, J.
Simonova, M.
Flisiak, R.
TRANSPLANTATION, 2016, 100 : S93 - S93
[46] MALACHITE-II: PHASE 3B TRIAL OF OMBITASVIR/PARITAPREVIR/R AND DASABUVIR plus RIBAVIRIN OR TELAPREVIR plus PEGINTERFERON/RIBAVIRIN IN PEGINTERFERON/RIBAVIRIN TREATMENT-EXPERIENCED ADULTS WITH HCV GENOTYPE 1
Dore, G.
Knysz, B.
Luo, Y.
Janczewska, E.
Streinu-Cercel, A.
Caruntu, F. A.
Motoc, A.
Mazur, W.
Shaw, D.
Tornai, I.
Sasadeusz, J.
Skoien, R.
Sullivan, D.
Liu, X.
Podsadecki, T.
JOURNAL OF HEPATOLOGY, 2015, 62 : S656 - S657
[47] MALACHITE-II: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir plus Ribavirin or Telaprevir plus Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With HCV Genotype 1
Dore, Gregory J.
Knysz, Brygida
Luo, Yan
Janczewska, Ewa
Streinu-Cercel, Adrian
Caruntu, Florin A.
Motoc, Adriana
Mazur, Wlodzimierz
Shaw, David R.
Tornai, Istvan
Sasadeusz, Joseph
Skoien, Richard
Sullivan, Danielle
Liu, Xuan
Podsadecki, Thomas
GASTROENTEROLOGY, 2015, 148 (04) : S1084 - S1085
[48] EXPOSURE-SAFETY RESPONSE RELATIONSHIP FOR ABT-450/RITONAVIR, OMBITASVIR, DASABUVIR AND RIBAVIRIN IN HEPATITIS C GENOTYPE 1 VIRUS-INFECTED SUBJECTS IN PHASE III STUDIES.
Lin, C.
Menon, R.
Liu, W.
Mensing, S.
Podsadecki, T.
Shulman, N.
DaSilva-Tillmann, B.
Awni, W.
Dutta, S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S25 - S26
[49] TURQUOISE-II: Trends in Liver Fibrosis Testing, Hepatic Synthetic Function, and Platelet Counts at Baseline and 12 Weeks After Treatment With ABT-450/r/Ombitasvir and Dasabuvir With Ribavirin in HCV Genotype 1-Infected Patients with Cirrhosis
Shiffman, Mitchell L.
Kowdley, Kris V.
Zeuzem, Stefan
Mutimer, David J.
Bourliere, Marc
Berg, Thomas
Lee, Samuel S.
Lovell, Sandra S.
Canizaro, Leticia
Trinh, Roger
Neff, Guy
Kwo, Paul Y.
HEPATOLOGY, 2014, 60 : 1152A - 1152A
[50] 99.7% Sustained Virologic Response Rate in 369 HCV Genotype 1b-Infected Patients Treated With Label-Recommended Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin
Jacobson, Ira M.
Dufour, Jean-Francois
Wedemeyer, Heiner
Bernstein, David
Colombo, Massimo
Romero-Gomez, Manuel
Reau, Nancy
Trinh, Roger
Xie, Wangang
Enejosa, Jeffrey
Cohen, Daniel
Martinez, Marisol
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S850 - S851

← 1 2 3 4 5 →